These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8503251)

  • 1. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy.
    Fruehauf S; Fiehn C; Haas R; Doehner H; Hunstein W
    Acta Haematol; 1993; 89(2):91-3. PubMed ID: 8503251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interferon-alpha therapy in the myeloproliferative variants of hypereosinophilic syndrome].
    Kobayashi M; Katayama T; Ochiai S; Yoshida M; Kaito K; Masuoka H; Shimada T; Nishiwaki K; Sakai O
    Rinsho Ketsueki; 1993 Mar; 34(3):367-72. PubMed ID: 8479090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines.
    Krishnaswamy G; Smith JK; Srikanth S; Chi DS; Kalbfleisch JH; Huang SK
    J Interferon Cytokine Res; 1996 Oct; 16(10):819-27. PubMed ID: 8910767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.
    Balleari E; Bason C; Visani G; Gobbi M; Ottaviani E; Ghio R
    Haematologica; 1994; 79(1):7-12. PubMed ID: 15378942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypereosinophilic syndrome treated with alpha-interferon and granulocyte colony-stimulating factor but complicated by nephrotoxicity.
    Hansen PB; Johnsen HE; Hippe E
    Am J Hematol; 1993 May; 43(1):66-8. PubMed ID: 7686334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term remission of neutropenia in Felty's syndrome after a short GM-CSF treatment.
    Pereira J; Velloso ED; Loterio HA; Laurindo IM; Chamone DA
    Acta Haematol; 1994; 92(3):154-6. PubMed ID: 7871957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-5 is the predominant eosinophilopoietin produced by cloned T lymphocytes in hypereosinophilic syndrome.
    Schrezenmeier H; Thomé SD; Tewald F; Fleischer B; Raghavachar A
    Exp Hematol; 1993 Feb; 21(2):358-65. PubMed ID: 8425573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease.
    Conran N; Saad ST; Costa FF; Ikuta T
    Ann Hematol; 2007 Apr; 86(4):255-61. PubMed ID: 17205286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha-Interferon treatment for idiopathic hypereosinophilic syndrome.
    Bockenstedt PL; Santinga JT; Bolling SF
    Am J Hematol; 1994 Mar; 45(3):248-51. PubMed ID: 8296798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis.
    Bourantas KL; Tsiara S; Christou L; Repousis P; Konstantinidou P; Bai M; Seferiadis K
    Acta Haematol; 1996; 96(2):79-82. PubMed ID: 8701705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor.
    Bochner BS; Friedman B; Krishnaswami G; Schleimer RP; Lichtenstein LM; Kroegel C
    J Allergy Clin Immunol; 1991 Oct; 88(4):629-36. PubMed ID: 1918729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5.
    Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M
    Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.
    Tatsis E; Schnabel A; Gross WL
    Ann Intern Med; 1998 Sep; 129(5):370-4. PubMed ID: 9735064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.
    Butterfield JH
    Acta Haematol; 2005; 114(1):26-40. PubMed ID: 15995323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS.
    Krown SE; Paredes J; Bundow D; Polsky B; Gold JW; Flomenberg N
    J Clin Oncol; 1992 Aug; 10(8):1344-51. PubMed ID: 1634925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma.
    Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
    Urol Int; 1998; 61(4):215-9. PubMed ID: 10364752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis c.
    Carreño V; Martín J; Pardo M; Brotons A; Anchía P; Navas S; Fernández M; Arocena C; Quiroga JA
    Cytokine; 2000 Feb; 12(2):165-70. PubMed ID: 10671303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.